M. Lepper, A. Simon, C. Marienfeld
Oct 1, 1957
Citations
0
Influential Citations
10
Citations
Journal
Annals of the New York Academy of Sciences
Abstract
It has been found that in human subjects the administration of sulfamethoxypyridazine* (3-sulfonamido-6-methoxypyridazine) is followed by high serum concentrations for 24 hours and by moderate concentrations for over 100 hours.', Moreover, the antibacterial activity has been said to be of the same order of magnitude as that of sulfadiazine, and the toxicity has been reported to be low in animals and, thus far, in human patients. For this reason sulfamethoxypyridazine promises special usefulness in situations where sulfonamides have been of value, particularly where they have been used over prolonged periods of time. One such situation has been the use of these drugs for the prevention of implantation of group-A Streptococcus pyogetzes in patients who have previously had rheumatic fever, in an attempt to reduce the number of recurrences and minimize progressive damage.3-5 However, the currently recommended use of 1 gm. of sulfadiazine daily for children weighing over 60 lb., and one half as much for the smaller child6 has suffered from a serious lack of patient cooperation. If sulfamethoxypyridazine could be used for this type of prophylaxis, with less frequent administration required, greater patient cooperation and reliability might be achieved. hloreover, the total required dosage would be less and, therefore, ultimately more economical. This report presents preliminary results of an attempt to develop a satisfactory method by which sulfamethoxypyridazine could be used conveniently and economically in the prophylaxis of streptococcal infections in rheumatic subjects.